If this is a unique species-specific feature of canine GB NEN, gastrin expression could be targeted therapeutically to limit clinical signs and reduce tumor burden, as described in other gastrin-secreting canine neuroendocrine tumors [5,6,7,8,9,10]. This evidence concerns the gene GAST and neuroendocrine neoplasm.